Medicine guide
Enerzair Breezhaler
·
- Prescription status not stated
- Breathing, airways, allergies and cough
- Active substance
- Indacaterol;glycopyrronium bromide;mometasone
- Made by
- Novartis Europharm Limited
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Enerzair Breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.
From the official label · 2026-09-30 · European Medicines Agency
Details
| Made by | Novartis Europharm Limited |
|---|---|
| Active substance | Indacaterol;glycopyrronium bromide;mometasone |
| Used in | Breathing, airways, allergies and cough |
| Classification | R03AL · Breathing, airways, allergies and cough |
| Authorised on | 2020-07-03 |
| Last updated by the regulator | 2025-11-20 |
| EMA product number | EMEA/H/C/005061 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).